HLB "Lenvatinib, Multiple Papers Presented at 2021 European Society for Medical Oncology... Another 'Complete Remission'"

[Asia Economy Reporter Hyunseok Yoo] HL Biopharma announced on the 14th that the abstract of the paper on Lenvatinib was released for the European Society for Medical Oncology 2021 (ESMO Congress 2021) online meeting.

The European Society for Medical Oncology is the most prestigious academic conference in the field of cancer research, attended annually by about 20,000 global cancer researchers, oncologists, and bio-industry professionals. This year, it will be held online from the 16th to the 21st.

At this conference, HL Biopharma will present 13 papers related to Lenvatinib (Chinese name Apatinib), for which it holds global rights. Once again, the outstanding efficacy of Lenvatinib for various indications will be demonstrated. In particular, Hansoh Pharmaceutical, which holds the Chinese distribution rights for Lenvatinib, will present two clinical results in poster format.

In a phase 2 clinical trial for liver cancer patients conducted by Guangzhou University in China under the leadership of Hansoh Pharmaceutical, 26 patients with advanced severe liver cancer were treated with a combination of hepatic arterial infusion chemotherapy (HAIC) and Lenvatinib (VEGFR inhibitor). The clinical results showed complete remission in 2 patients, an objective response rate (ORR) of 61.54%, and a disease control rate (DCR) of 92.31%. Additionally, the proportion of patients achieving progression-free survival (PFS) without tumor growth for 6 months was 73.7%, and the overall survival (OS) rate at 12 months was 90.7%, confirming high therapeutic efficacy for refractory patients.

Clinical results were also presented from a study at Huan University in China involving 22 cervical cancer patients treated with a combination of Lenvatinib, the immune checkpoint inhibitor Camrelizumab (PD-1 inhibitor), and the cytotoxic chemotherapy agent Paclitaxel as second-line therapy. The results showed 5 cases of complete remission and an ORR of 71%. The researchers involved stated that the combination therapy with Lenvatinib significantly increased the ORR and demonstrated manageable side effects, confirming its potential as a second-line treatment for cervical cancer.

Furthermore, real-world data from Nanchang University in China involving 257 gastric cancer patients treated with Lenvatinib monotherapy was presented. Among all patients, 103 (40.08%) received Lenvatinib as first-line therapy, and 64 (24.9%) as second-line therapy, resulting in an ORR of 25.78% and a DCR of 79.69%. The researchers plan to continue clinical trials to secure sufficient data.

In addition, poster presentations on multiple papers related to non-small cell lung cancer, colorectal cancer, ovarian cancer, and others are scheduled, confirming not only the high efficacy and safety of Lenvatinib but also its broad combinability with immunotherapy and cytotoxic chemotherapy agents.

This content was produced with the assistance of AI translation services.